Fixed dose drug combinations–are they pharmacoeconomically sound? Findings and implications especially for lower- and middle-income countries

Author collaboration, Brian Godman (Coresponding Author), Konstantīns Logviss

Research output: Contribution to journalArticlepeer-review

5 Citations (Scopus)

Abstract

Introduction: There are positive aspects regarding the prescribing of fixed dose combinations (FDCs) versus prescribing the medicines separately. However, these have to be balanced against concerns including increased costs and their irrationality in some cases. Consequently, there is a need to review their value among lower- and middle-income countries (LMICs) which have the greatest prevalence of both infectious and noninfectious diseases and issues of affordability. Areas covered: Review of potential advantages, disadvantages, cost-effectiveness, and availability of FDCs in high priority disease areas in LMICs and possible initiatives to enhance the prescribing of valued FDCs and limit their use where there are concerns with their value. Expert commentary: FDCs are valued across LMICs. Advantages include potentially improved response rates, reduced adverse reactions, increased adherence rates, and reduced costs. Concerns include increased chances of drug:drug interactions, reduced effectiveness, potential for imprecise diagnoses and higher unjustified prices. Overall certain FDCs including those for malaria, tuberculosis, and hypertension are valued and listed in the country’s essential medicine lists, with initiatives needed to enhance their prescribing where currently low prescribing rates. Proposed initiatives include robust clinical and economic data to address the current paucity of pharmacoeconomic data. Irrational FDCs persists in some countries which are being addressed.

Original languageEnglish
Pages (from-to)1-26
Number of pages26
JournalExpert Review of Pharmacoeconomics and Outcomes Research
Volume20
Issue number1
DOIs
Publication statusPublished - 2 Jan 2020

Keywords

  • adherence
  • Fixed dose combinations
  • infectious diseases
  • lower and middle income countries
  • medicines
  • non-communicable diseases
  • pharmacoeconomics

Field of Science

  • 3.1 Basic medicine

Publication Type

  • 1.1. Scientific article indexed in Web of Science and/or Scopus database

Fingerprint Dive into the research topics of 'Fixed dose drug combinations–are they pharmacoeconomically sound? Findings and implications especially for lower- and middle-income countries'. Together they form a unique fingerprint.

Cite this